Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47353
Title: Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study
Authors: Capkin E.
Yazıcı A.
Karkucak M.
Durmaz Y.
Toprak M.
Ataman Ş.
Şahin N.
Cuzdan, Nihan
Kasapoglu Aksoy, Meliha
Onder, Mustafa Erkut
Serdaroglu Beyazal, Munevver
Mesci, Nilgun
Baykul, Merve
Alkan Melikoglu, Meltem
Alkan, Hakan
Dulgeroglu, Deniz
Cengiz, Ahmet Kivanc
Nas, Kemal
Balevi Batur Elif
Caliskan Uckun, Asli
Deveci, Hulya
Erol, Kemal
Albayrak Gezer, Ilknur
Akgol, Gurkan
Duruoz, Mehmet Tuncay
Kucukakkas, Okan
Sarikaya, Selda
Rezvani, Aylin
Atan, Tugba
Gogus, Feride
Caglayan, Gokhan
Keskin, Yasar
Bulut Keskin, Ayse Selcen
Oz, Nuran
Yilmaz, Gurdal
Keywords: Biologic agents
Hepatitis
Inflammatory arthritis
Viral reactivation
Publisher: Springer Science and Business Media Deutschland GmbH
Abstract: To evaluate of hepatitis serology and reactivation frequency in patients with rheumatic disease receiving biologic agents. Our study included patients with inflammatory rheumatic diseases from 23 centers, who were followed up with biological therapy. Demographic and clinical characteristics of the patients, duration of drug use and hepatitis serology and the state of viral reactivation were analyzed. A total of 4060 patients, 2095 being males, were included in our study. Of the patients, 2463 had Ankylosing Spondylitis (AS), 1154 had Rheumatoid Arthritis (RA), 325 had Psoriatic Arthritis (PsA), and 118 had other inflammatory rheumatic diseases. When the viral serology of the patients was evaluated, 79 patients (2%) who were identified as HBs Ag positive, 486 (12%) patients who were HBs Ag negative and anti-HBc IgG positive and 20 patients (0.5%) who were anti-HCV positive. When evaluated on a disease-by-disease basis, the rate of HBsAg was found to be 2.5% in RA, 2% in AS and 0.9% in PsA. Viral reactivation was detected in 13 patients while receiving biologic agents. HBs Ag was positive in nine patients with reactivation and negative in four patients. Anti-HBc IgG, however, was positive. Six of these patients had AS, four had RA, and three had PsA. The development of hepatitis reactivation in 11.4% of HBs Ag positive patients and 0.82% of anti-HBc IgG positive patients due to the use of biologic agents is an important problem for this group of patients. Antiviral prophylaxis is recommended to be started especially in patients who are HBs Ag positive and who are using biologic agents due to viral reactivation. Therefore, it is important to carry out hepatitis screenings before biologic agent treatment and to carefully evaluate the vaccination and prophylaxis requirements. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Description: Article; Early Access
URI: https://doi.org/10.1007/s00296-022-05169-2
https://hdl.handle.net/11499/47353
ISSN: 0172-8172
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Show full item record



CORE Recommender

SCOPUSTM   
Citations

1
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

2
checked on Oct 31, 2024

Page view(s)

60
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.